Author Archive: Jim Greenwood

Jim Greenwood

Jim joined BIO as President & CEO in 2005 after representing the eighth district of Pennsylvania in the U.S. House of Representatives for six terms.  He had worked with BIO while in Congress on stem cell research and other health issues, and has since learned so much about the many applications of the science in food and agriculture and in industrial and environmental biotechnology.

Due to its revolutionary research and development in issues ranging from feeding the world by increasing crop yields to healing the world with new medicines to providing cleaner sources of energy, Jim is a passionate champion for biotechnology. When visiting member companies, he is inspired by executives and scientists who are united in their mission to help patients, farmers and other consumers lead a better life.

Prior to Congress, Jim served in the Pennsylvania House of Representatives and Pennsylvania Senate for six years each.  He and his wife Tina live in historic Washington Crossing, Pennsylvania (where he has participated in the re-enactment of George Washington crossing the Delaware River on Christmas Day in 1776). He enjoys fishing, birding and scuba diving.

You can find him on Facebook at https://www.facebook.com/jamescgreenwood.

Latest Posts

Jim Greenwood guest appearance on CNBC’s “Squawk Box” during this morning’s “Health Care Summit” special

BIO President and CEO Jim Greenwood joined former HHS Secretary Tommy Thompson and former FDA Deputy Commissioner Scott Gottlieb to discuss biosimilars and the importance of preserving innovation as the nation moves to reform our health care system.

Jim's Corner  |  Leave a comment  |  Email This Post

Clearing Another Hurdle on the Pathway to Biosimilars

The House Energy and Commerce Committee, by a vote of 47 to 11, overwhelmingly adopted an amendment creating a regulatory pathway for biosimilars that will provide 12 years of data exclusivity for innovative biologics. The strong bipartisan support for this amendment to the America’s Affordable Health Choices Act marks the second win this month for a fair and balanced approach to biosimilars market entry. This vote was a clear victory for patients. The ALS Association Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Patient groups join call for data protection

Biomedical innovation is not only key to our industry’s future, but more importantly, continued medical breakthroughs are vital to patients living with debilitating diseases and their families. Without ongoing progress in our industry, patients of today and tomorrow have limited hope for future cures and therapies. Many patient groups have entered the debate on Capitol Hill over establishing a pathway for approval of biosimilars because they know how critical continued innovation is to finding new Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Victory on Biosimilars in Senate HELP Committee – But Still a Long Way from the Finish Line

Last evening the Senate Health, Education, Labor and Pensions (HELP) Committee adopted an amendment to the healthcare reform package that provided 12 years of data exclusivity for innovative biologics. This event was a significant victory for our companies and for patients. Two and a half years ago Senator Clinton and Congressman Waxman introduced bills that provided zero years of data exclusivity. Following extensive negotiations, Senators Kennedy, Enzi, Hatch, Schumer and Clinton agreed to a bill Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

The Washington Post: Special section on biotechnology

As part of our public education/industry branding campaign, BIO sponsored a special section on biotechnology which ran in The Washington Post on Wednesday, June 24: http://ukpublic.mediaplanet.com/biotechwashpostfinal.pdf The insert provides a general introduction to biotech, emphasizing how biotechnology is helping to heal, feed and fuel the world.  We also used the piece to disseminate some of our key messages surrounding biosimilars. The special section was included in the 713,000 printed copies of the Post distributed in Read More >

Jim's Corner  |  Leave a comment  |  Email This Post